Now showing items 1-1 of 1

    • Drugging the Undruggable: Advances on RAS Targeting in Cancer. 

      Molina-Arcas, M; Samani, A; Downward, J (MDPI, 2021-06-10)
      Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of ...